1.85, p Ͻ 0.05). Patients averaged 0.51 physician visits for GERD/UGIs. QoL was significantly lower in symptomatic than nonsymptomatic persons for all domains. Overall PGWBI mean (71.8 versus 85.6, p Ͻ 0.01) correlated with increased physician visits (p Ͻ 0.001). Projecting annually for the US, Ͼ1 billion additional workdays are lost, costing $100 billion (1.5% of GDP). CONCLUSIONS: GI symptoms constitute a major health problem with substantial health and economic impact. Open access services allow direct referral by primary care doctors without an opinion from a gastroenterologist. Our aim was to measure this new service's effect on prescribing costs.
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THE EFFECT OF AN OPEN ACCESS ENDOSCOPY SERVICE ON PRESCRIBING COSTS OF ULCER-HEALING DRUGS
METHODS:
The study used all patients from Tayside who had complete prescribing data for 1 year before referral and 1 year after endoscopy and had a diagnosis recorded at endoscopy. The main outcome measure was the change in prescribing costs for dispensed ulcer-healing drugs (UHDs) in the 4 months after endoscopy compared to the 4 months before referral. RESULTS: Of the 1063 patients referred, 883 were resident in Tayside and had complete data. The results of endoscopy were normal in 311 (35%), esophagitis in 323 (37%), ulcer in 55 (6%), both in 33 (4%), and other upper GI pathology in 161 (18%). Significant independent predictors of prescribing cost after endoscopy were: the cost of drugs before referral, the diagnosis at endoscopy, and age (p ϭ 0.0001 by both generalized linear modeling and a nonparametric ranking test). Variables that were not significantly associated with prescribing cost after endoscopy were: sex, interval between referral and endoscopy, and previous history of either UHDs, endoscopy, or hospitalization for GI event. Controlling for age and cost of drugs before referral, there was a mean decrease in prescribing costs of £11 per patient with normal endoscopy. Prescribing costs increased by £33 for esophagitis, by £25 for ulcer, by £41 for both, and by £23 for other pathology. CONCLUSIONS: Open access endoscopy was associated with increased cost of prescribing for UHDs, mainly because the procedure revealed pathology in 65% of cases.
